Correlation Between Tcr2 Therapeutics and PDS Biotechnology

Can any of the company-specific risk be diversified away by investing in both Tcr2 Therapeutics and PDS Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tcr2 Therapeutics and PDS Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Tcr2 Therapeutics and PDS Biotechnology Corp, you can compare the effects of market volatilities on Tcr2 Therapeutics and PDS Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tcr2 Therapeutics with a short position of PDS Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tcr2 Therapeutics and PDS Biotechnology.

Diversification Opportunities for Tcr2 Therapeutics and PDS Biotechnology

-0.19

Correlation Coefficient

Tcr2 Therapeutics  PDS Biotechnology

Good diversification

The 3 months correlation between Tcr2 and PDS is -0.19. Overlapping area represents the amount of risk that can be diversified away by holding Tcr2 Therapeutics and PDS Biotechnology Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on PDS Biotechnology Corp and Tcr2 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tcr2 Therapeutics are associated (or correlated) with PDS Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of PDS Biotechnology Corp has no effect on the direction of Tcr2 Therapeutics i.e., Tcr2 Therapeutics and PDS Biotechnology go up and down completely randomly.

Pair Corralation between Tcr2 Therapeutics and PDS Biotechnology

Given the investment horizon of 90 days Tcr2 Therapeutics is expected to generate 0.98 times more return on investment than PDS Biotechnology. However, Tcr2 Therapeutics is 1.02 times less risky than PDS Biotechnology. It trades about 0.07 of its potential returns per unit of risk. PDS Biotechnology Corp is currently generating about -0.04 per unit of risk. If you would invest  119.00  in Tcr2 Therapeutics on August 31, 2024 and sell it today you would earn a total of  29.00  from holding Tcr2 Therapeutics or generate 24.37% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	21.13%
Values	Daily Returns

Tcr2 Therapeutics  vs.  PDS Biotechnology Corp

Tcr2 Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Tcr2 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Tcr2 Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.

PDS Biotechnology Corp

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days PDS Biotechnology Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Tcr2 Therapeutics and PDS Biotechnology

The main advantage of trading using opposite Tcr2 Therapeutics and PDS Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tcr2 Therapeutics position performs unexpectedly, PDS Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PDS Biotechnology will offset losses from the drop in PDS Biotechnology's long position.

The idea behind Tcr2 Therapeutics and PDS Biotechnology Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.